Philip Greenberg is a Professor of Medicine, Oncology and Immunology at the University of Washington and Head of Program in Immunology at Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics and Affini-T.